Navigation Links
NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
Date:5/7/2008

as evidenced by a steep increase of plasma NKTR-118 concentration. Plasma concentrations of NKTR-118-glucuronide were approximately 100-fold less than plasma NKTR-118 concentrations. Studies have shown that the bioavailability of oral naloxone is limited by first-pass metabolism of naloxone.(1)

"The prevalence and impact of opioid-bowel dysfunction among chronic pain patients are underestimated today," said Sunil J. Panchal, M.D., President of the National Institute of Pain and the Coalition for Pain Education (COPE) Foundation. "The condition can have a serious deleterious impact on a patient's quality of life and can also limit chronic pain management treatments. There is a clear need for an oral therapy that targets the underlying cause of OBD while preserving the desired analgesic effects of opioid treatment."

About the Phase 1 Clinical Trial

The primary objective of this Phase 1 multi-dose, double-blind, randomized, placebo-controlled study was to evaluate the safety and tolerability of multiple doses of oral NKTR-118 in healthy human subjects not receiving opioid therapy. A total of 32 subjects enrolled in the trial. The secondary objective of the trial was to evaluate the pharmacokinetics of oral NKTR-118 and its metabolite (NKTR-118 glucuronide) following twice-daily oral administration for seven days. Escalating doses up to 250 mg twice daily were studied. Subjects were randomized 3:1 to NKTR-118 or placebo twice daily (every 12 hours) for seven days, with a single dose on the eighth day.

Prior Clinical Study Results for NKTR-118

Nektar previously presented results from a proof-of-principle, single-dose Phase 1 study at the American College of Clinical Pharmacology Meeting (ACCP) conference in September of 2007. In this proof-of-principle study, single oral doses of NKTR-118 antagonized morphine-induced delay in gastrointestinal transit time demonstrating the potential of the drug to relieve constipation. Further, no dimi
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
2. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
3. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
4. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
7. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
8. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
9. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
10. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
11. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... RealMed has been ranked the ... 2009 Top 20 Best in KLAS ... RealMed is a dynamic revenue cycle management ... between healthcare providers and all ... specializing in vendor performance measurement in the ...
(Date:12/16/2009)... CareCentrix, Inc ., the nation,s leading provider ... that it has been awarded Health Utilization Accreditation ... organization that establishes quality standards for the health ... trained, qualified clinical personnel conduct and oversee the ... appeals process is in place, and that medical ...
(Date:12/16/2009)... 16 Siemens Healthcare today ... to help healthcare ... deadlines defined within the HITECH provision of ... Featuring zero-percent interest terms for ... defer up-front payments associated with their technology ...
Breaking Medicine Technology:RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3CareCentrix Receives URAC Health Utilization Management Accreditation 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4Insulet Corporation to Present at Upcoming Investor Conferences 53953 1Insulet Corporation to Present at Upcoming Investor Conferences 53953 2Garry OGrady Appointed Senior Vice President and General Manager of Pharmaceutical Institute 53951 1Garry OGrady Appointed Senior Vice President and General Manager of Pharmaceutical Institute 53951 2Delays in UK child brain tumor diagnosis 53949 1Delays in UK child brain tumor diagnosis 53949 2
... 15 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ) ... timing,of its announcement of results for the CLIRS ... (omiganan pentahydrochloride 1% topical gel),for the prevention of ... discussions with the U.S. Food and Drug,Administration (FDA) ...
... DURHAM, N.C., Sept. 15 Less than ... are eventually published in,medical journals, according to a ... (LOGO: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO ), Drs. ... Washington and,Fred Hutchinson Cancer Research Center, Seattle, searched ...
Other Medicine Technology:Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline 2Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline 3Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline 4Most Cancer Treatment Studies Aren't Published, Study Finds 2Most Cancer Treatment Studies Aren't Published, Study Finds 3
(Date:12/17/2009)... science-based products from MediNiche provide alternative natural relief prior to ... ... MO (PRWEB) December 17, 2009 -- D-Psoria products ... and flaking associated with severe skin conditions . ... the U.S. by MediNiche Pharmaceuticals, St. Louis, Missouri., ...
(Date:12/17/2009)... & Nathan law firm, litigators of complex personal injury and insurance ... , ... Tulsa, OK (Lexis Nexis) December 17, 2009 -- ... 20 years of experience handling personal injury and insurance coverage disputes, ... the top attorneys in the state of Oklahoma for 2009-2010., , ...
(Date:12/16/2009)... -- Health care sector revenue increased by 5.7 ... $1.66 trillion in 2007, according to new data ... classified under the North American Industry Classification System ... ,, These figures come from the 2008 ... , a series of tables which provides estimates ...
(Date:12/16/2009)... CHASE, Md., Dec. 16 New Enterprise ... firm, today announced that one of its portfolio ... agreement to be acquired by Ethicon, Inc., a ... for approximately $785 million (net of estimated cash ... technology company dedicated to designing, developing and commercializing ...
(Date:12/16/2009)... has never felt so good for "The Biggest Loser" ... means continuing to make smart choices everyday to help ... healthy choice that is an important part of living ... Every glass of milk has nine essential nutrients like ... blood pressure, and calcium and vitamin D for strong ...
Breaking Medicine News(10 mins):Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3
... uncovered the secrets of the deadly Spanish flu that in 1918 ... ,The pandemic took lives of more people than ... virus was not understood then. ,Dr John Kash, of the University ... infecting mice with a reconstructed form of the 1918 virus and ...
... the September 27 issue of JAMA says that initial ... HIV positive patients has little or no effect on ... conflicts in opinion as to when antiretroviral therapy must ... of progressive human immunodeficiency virus (HIV) disease and a ...
... the turn of the 20th century, tobacco baron James Duke ... of 430 million, jabbed his finger at a map of ... sell cigarettes." ,One hundred years on, Duke's prophesy about ... has since grown to 1.3 billion, has been realised on ...
... from the Johns Hopkins University and other institutions have ... as Lynch syndrome// , which predisposes families to develop ... an individual’s detailed family history of colorectal and endometrial ... manifest themselves—in the form of tumors. It can assess ...
... of food labels and test if it meets the ... Services //embarked on a survey involving 200 primary care ... reading food-labels, as a prelude to making a purchase, ... that consumers often check on food labels would most ...
... of employers has revealed that premiums for employer-based health ... inflation and wages, Fo the seventh straight year.// ... group and the Health Research and Educational Trust released ... premium increase was 7.7 percent, in 2006, the least ...
Other Medicine News:Health News:Spanish flu virus – secrets uncovere 2Health News:HIV RNA Level Seen As Little Value In Predicting Treatment 2Health News:World's 3 out of 10 Cigarettes Smoked in China 2Health News:Model Predicts Colon Cancer Inheritable Genetic Defects 2Health News:Premiums for Health insurance Soar 2
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
... Used for catheter positioning and exchange in ... the wire guide coils allows utilization of ... smooth transition to a very flexible tip. ... is the most rigid coiled wire guide ...
... Used for catheter positioning ... procedures. Increased inner diameter ... allows utilization of an ... while maintaining tip flexibility. ...
Medicine Products: